What is the recommended starting dose, titration schedule, contraindications, and monitoring for d‑amphetamine extended‑release (ER) in an adult patient with ADHD?

d-Amphetamine Extended-Release (ER) for Adult ADHD

Starting Dose

For adults with ADHD, initiate d-amphetamine ER at 20 mg once daily in the morning upon awakening. 1 This represents the FDA-approved starting dose for adults who are either beginning treatment for the first time or switching from another medication. 1

• When clinical judgment indicates a lower initial dose is appropriate, you may begin with 10 mg once daily in the morning, then titrate upward. 1
• The 20 mg starting dose is supported by randomized controlled trial data showing efficacy and tolerability in adults with ADHD. 2, 3

Titration Schedule

Increase the dose in increments of 5–10 mg at weekly intervals based on symptom response and tolerability. 4, 1

• Obtain standardized ADHD rating scales from the patient (and ideally a significant other) before each dose increase to objectively measure symptom improvement. 4, 5
• Monitor for target symptoms including inattention, hyperactivity, impulsivity, and functional impairment across work, home, and social settings. 4, 5
• The typical therapeutic range for adults is 10–50 mg daily, with maximum recommended doses reaching 40 mg for amphetamine salts in most guidelines. 4, 5, 6
• Some patients may require up to 0.9 mg/kg or 65 mg total daily dose when lower doses prove insufficient and no dose-limiting side effects occur, though this requires clear documentation. 5, 6

Systematic titration to optimal effect is more important than strict mg/kg calculations—approximately 70% of patients respond optimally when proper titration protocols are followed. 5, 6

Administration Timing

Administer d-amphetamine ER once daily in the morning upon awakening to maximize daytime symptom control and minimize insomnia. 1

• Afternoon doses should be avoided due to the potential for sleep disruption. 1
• The extended-release formulation provides approximately 12 hours of symptom coverage, eliminating the need for multiple daily doses. 3, 7
• If evening symptoms remain problematic despite optimized morning dosing, consider adding a small immediate-release dose (5 mg) in the mid-afternoon rather than increasing the morning dose further. 4, 5

Contraindications

Absolute contraindications include: 4, 6, 1

• Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation—risk of hypertensive crisis. 4, 6
• Active psychotic disorder or mania. 4, 6
• Symptomatic cardiovascular disease or uncontrolled hypertension. 4, 6, 8
• Known hypersensitivity to amphetamines. 4, 6
• Glaucoma, hyperthyroidism. 4, 6

Relative contraindications requiring caution: 4, 6

• History of substance use disorder—consider long-acting formulations with lower abuse potential and implement close monitoring. 4, 6
• Seizure disorder—ensure stability on anticonvulsant therapy before initiating. 4, 6
• Unstable mood disorder—stabilize mood first, though secondary depression may improve with ADHD treatment. 4, 6
• Marked anxiety—recent data indicate stimulants do not necessarily exacerbate anxiety and may improve comorbid anxiety symptoms. 4, 6

Baseline Monitoring Requirements

Before initiating d-amphetamine ER, perform the following assessments: 4, 5, 6

• Measure blood pressure and pulse in both seated and standing positions. 4, 5, 6
• Obtain detailed personal and family cardiac history, specifically screening for sudden cardiac death in relatives younger than 50 years, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, Long QT syndrome, unexplained syncope, chest pain, or palpitations. 4, 6
• Document all prior ADHD-related treatments including medications, doses, duration, response, side effects, and adherence. 4, 6
• Screen adolescents and adults for substance use risk. 4, 6
• Record baseline height and weight (particularly relevant for younger patients). 4, 5

Ongoing Monitoring During Titration

During the titration phase (first 4–6 weeks), conduct weekly assessments including: 4, 5, 6

• Blood pressure and pulse measurement at each dose adjustment. 4, 5, 6
• ADHD symptom rating scales to assess therapeutic response. 4, 5
• Systematic inquiry about side effects including decreased appetite, insomnia, headache, irritability, and social withdrawal. 4, 5
• Sleep quality and appetite changes. 4, 5, 8

Maintenance Phase Monitoring

Once the patient is stable on a therapeutic dose: 4, 5, 6

• Check blood pressure and pulse quarterly in adults. 4, 6
• Measure height and weight at every visit in children and adolescents; periodically in adults. 4, 5, 6
• Schedule monthly visits initially, then quarterly once stability is achieved. 5, 8
• Monitor for tolerance development, which is rare with appropriate dosing. 4, 6

Common Adverse Effects and Management

The most frequent side effects include: 2, 3, 9

• Decreased appetite (>10% of patients)—administer medication after meals to lessen suppression. 4, 2, 3
• Insomnia (>10% of patients)—ensure morning dosing and avoid late-day administration. 4, 2, 3
• Dry mouth, headache (>10% of patients). 2, 3
• Modest increases in blood pressure (≈3–5 mm Hg) and heart rate (≈5–10 bpm). 8

Most treatment-emergent adverse events are mild to moderate in severity. 2 If side effects become intolerable, consider dose reduction, switching to an alternative stimulant class (methylphenidate), or transitioning to a non-stimulant option. 4, 5, 9

Expected Efficacy

Amphetamine-based stimulants achieve 70–80% response rates in adults with ADHD when properly titrated. 5, 6, 9, 10

• Therapeutic effects manifest within days, allowing rapid assessment of efficacy. 4, 5, 8
• Effect sizes for amphetamines are approximately 1.0, the largest among all ADHD medication classes. 5, 9, 10
• In head-to-head comparisons, amphetamines demonstrate superior efficacy to atomoxetine, modafinil, and methylphenidate in adults. 9, 10
• Approximately 40% of patients respond to both amphetamine and methylphenidate classes, while another 40% respond preferentially to only one class—if response is inadequate after proper amphetamine titration, trial methylphenidate before considering non-stimulants. 5, 8

Critical Pitfalls to Avoid

• Do not under-dose out of fear of side effects—systematic titration protocols enable roughly 70% of patients to achieve optimal response. 4, 5
• Do not base dosing on mg/kg calculations—response variability is not correlated with body weight; use systematic weekly titration instead. 4, 5
• Do not discontinue prematurely due to comorbid anxiety—evidence shows stimulants do not exacerbate anxiety and may yield higher response rates in anxious subgroups. 4, 6
• Do not assume the initial dose is adequate—most adults require titration to 20–40 mg daily for optimal ADHD control. 4, 5, 6
• Do not prescribe "as needed" or sporadic dosing—ADHD requires consistent daily symptom control to prevent functional impairment. 5, 8

Multimodal Treatment Approach

Combine pharmacotherapy with evidence-based psychosocial interventions for optimal functional outcomes. 4, 5, 8

• Cognitive Behavioral Therapy (CBT) specifically developed for ADHD is the most extensively studied psychotherapy and shows increased effectiveness when combined with medication. 5, 6, 8
• Mindfulness-Based Interventions help most profoundly with inattention symptoms, emotion regulation, executive function, and quality of life. 5, 6
• Psychoeducation about ADHD and its impact is a key component of comprehensive care. 5, 8